Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165840 · ClinicalTrials.gov registry record · Phase 4
Effect of Weight and/or Obesity on Dapsone Drug Concentrations
A Phase 4 study, sponsored by Texas Tech University Health Sciences Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT01165840: Completed Phase 4 study, sponsored by Texas Tech University Health Sciences Center.
NCT01165840 is a Phase 4 study that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 37 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01165840, a Phase 4 study, has completed, sponsored by Texas Tech University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study will find how weight affects the dosing of a drug called dapsone. Currently, the amount of dapsone a patient receives is the same regardless of the patient's weight.
Primary Outcome
Serum clearance of dapsone
Interventions
- DRUG Dapsone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-05 |
| Phase | Phase 4 |
What the finished NCT01165840 record still lists
NCT01165840 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Dapsone is the first listed.
NCT01165840 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01165840 about?
NCT01165840 is a clinical study titled "Effect of Weight and/or Obesity on Dapsone Drug Concentrations". This study will find how weight affects the dosing of a drug called dapsone. Currently, the amount of dapsone a patient receives is the same regardless of the patient's weight.
What is the current status of trial NCT01165840?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2010-07. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01165840?
The interventions under investigation include: Dapsone (DRUG).
Who is sponsoring clinical trial NCT01165840?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01165840's enrollment target sits among peer trials
37 1482nd of 2000 higher than 511 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia